198 related articles for article (PubMed ID: 33534128)
1. Digoxin treatment reactivates in vivo radioactive iodide uptake and correlates with favorable clinical outcome in non-medullary thyroid cancer.
Crezee T; Tesselaar MH; Nagarajah J; Corver WE; Morreau J; Pritchard C; Kimura S; Kuiper JG; van Engen-van Grunsven I; Smit JWA; Netea-Maier RT; Plantinga TS
Cell Oncol (Dordr); 2021 Jun; 44(3):611-625. PubMed ID: 33534128
[TBL] [Abstract][Full Text] [Related]
2. Autophagy activity is associated with membranous sodium iodide symporter expression and clinical response to radioiodine therapy in non-medullary thyroid cancer.
Plantinga TS; Tesselaar MH; Morreau H; Corssmit EP; Willemsen BK; Kusters B; van Engen-van Grunsven AC; Smit JW; Netea-Maier RT
Autophagy; 2016 Jul; 12(7):1195-205. PubMed ID: 27105307
[TBL] [Abstract][Full Text] [Related]
3. Vemurafenib Redifferentiation of BRAF Mutant, RAI-Refractory Thyroid Cancers.
Dunn LA; Sherman EJ; Baxi SS; Tchekmedyian V; Grewal RK; Larson SM; Pentlow KS; Haque S; Tuttle RM; Sabra MM; Fish S; Boucai L; Walters J; Ghossein RA; Seshan VE; Ni A; Li D; Knauf JA; Pfister DG; Fagin JA; Ho AL
J Clin Endocrinol Metab; 2019 May; 104(5):1417-1428. PubMed ID: 30256977
[TBL] [Abstract][Full Text] [Related]
4. Digitalislike Compounds Restore hNIS Expression and Iodide Uptake Capacity in Anaplastic Thyroid Cancer.
Tesselaar MH; Crezee T; Schuurmans I; Gerrits D; Nagarajah J; Boerman OC; van Engen-van Grunsven I; Smit JWA; Netea-Maier RT; Plantinga TS
J Nucl Med; 2018 May; 59(5):780-786. PubMed ID: 29242405
[TBL] [Abstract][Full Text] [Related]
5. Mitogen-Activated Protein Kinase Pathway Inhibition for Redifferentiation of Radioiodine Refractory Differentiated Thyroid Cancer: An Evolving Protocol.
Iravani A; Solomon B; Pattison DA; Jackson P; Ravi Kumar A; Kong G; Hofman MS; Akhurst T; Hicks RJ
Thyroid; 2019 Nov; 29(11):1634-1645. PubMed ID: 31637953
[No Abstract] [Full Text] [Related]
6. Pathological processes and therapeutic advances in radioiodide refractory thyroid cancer.
Tesselaar MH; Smit JW; Nagarajah J; Netea-Maier RT; Plantinga TS
J Mol Endocrinol; 2017 Nov; 59(4):R141-R154. PubMed ID: 28931558
[TBL] [Abstract][Full Text] [Related]
7. Digitalis-like Compounds Facilitate Non-Medullary Thyroid Cancer Redifferentiation through Intracellular Ca2+, FOS, and Autophagy-Dependent Pathways.
Tesselaar MH; Crezee T; Swarts HG; Gerrits D; Boerman OC; Koenderink JB; Stunnenberg HG; Netea MG; Smit JW; Netea-Maier RT; Plantinga TS
Mol Cancer Ther; 2017 Jan; 16(1):169-181. PubMed ID: 27837029
[TBL] [Abstract][Full Text] [Related]
8. Radioactive Iodine-Refractory Differentiated Thyroid Cancer and Redifferentiation Therapy.
Liu J; Liu Y; Lin Y; Liang J
Endocrinol Metab (Seoul); 2019 Sep; 34(3):215-225. PubMed ID: 31565873
[TBL] [Abstract][Full Text] [Related]
9. Dual inhibition of BRAF and MEK increases expression of sodium iodide symporter in patient-derived papillary thyroid cancer cells in vitro.
Ullmann TM; Liang H; Moore MD; Al-Jamed I; Gray KD; Limberg J; Stefanova D; Buicko JL; Finnerty B; Beninato T; Zarnegar R; Min IM; Fahey TJ
Surgery; 2020 Jan; 167(1):56-63. PubMed ID: 31585718
[TBL] [Abstract][Full Text] [Related]
10. A Novel Tyrosine Kinase Inhibitor Can Augment Radioactive Iodine Uptake Through Endogenous Sodium/Iodide Symporter Expression in Anaplastic Thyroid Cancer.
Oh JM; Baek SH; Gangadaran P; Hong CM; Rajendran RL; Lee HW; Zhu L; Gopal A; Kalimuthu S; Jeong SY; Lee SW; Lee J; Ahn BC
Thyroid; 2020 Apr; 30(4):501-518. PubMed ID: 31928162
[No Abstract] [Full Text] [Related]
11. Mediator complex subunit 16 is down-regulated in papillary thyroid cancer, leading to increased transforming growth factor-β signaling and radioiodine resistance.
Gao H; Bai P; Xiao L; Shen M; Yu Q; Lei Y; Huang W; Lin X; Zheng X; Wei T; Jiang Y; Ye F; Bu H
J Biol Chem; 2020 Jul; 295(31):10726-10740. PubMed ID: 32532820
[TBL] [Abstract][Full Text] [Related]
12. Robust Thyroid Gene Expression and Radioiodine Uptake Induced by Simultaneous Suppression of BRAF V600E and Histone Deacetylase in Thyroid Cancer Cells.
Cheng W; Liu R; Zhu G; Wang H; Xing M
J Clin Endocrinol Metab; 2016 Mar; 101(3):962-71. PubMed ID: 26751190
[TBL] [Abstract][Full Text] [Related]
13. Targeted Therapy in Advanced Thyroid Cancer to Resensitize Tumors to Radioactive Iodine.
Jaber T; Waguespack SG; Cabanillas ME; Elbanan M; Vu T; Dadu R; Sherman SI; Amit M; Santos EB; Zafereo M; Busaidy NL
J Clin Endocrinol Metab; 2018 Oct; 103(10):3698-3705. PubMed ID: 30032208
[TBL] [Abstract][Full Text] [Related]
14. Lithium as adjuvant to radioiodine therapy in differentiated thyroid carcinoma: clinical and in vitro studies.
Liu YY; van der Pluijm G; Karperien M; Stokkel MP; Pereira AM; Morreau J; Kievit J; Romijn JA; Smit JW
Clin Endocrinol (Oxf); 2006 Jun; 64(6):617-24. PubMed ID: 16712662
[TBL] [Abstract][Full Text] [Related]
15. Molecular mechanisms of radioactive iodine refractoriness in differentiated thyroid cancer: Impaired sodium iodide symporter (NIS) expression owing to altered signaling pathway activity and intracellular localization of NIS.
Oh JM; Ahn BC
Theranostics; 2021; 11(13):6251-6277. PubMed ID: 33995657
[TBL] [Abstract][Full Text] [Related]
16. Sinomenine Hydrochloride Promotes TSHR-Dependent Redifferentiation in Papillary Thyroid Cancer.
Zhang J; Zhao A; Jia X; Li X; Liang Y; Liu Y; Xie X; Qu X; Wang Q; Zhang Y; Gao R; Yu Y; Yang A
Int J Mol Sci; 2022 Sep; 23(18):. PubMed ID: 36142613
[TBL] [Abstract][Full Text] [Related]
17. Risk of Second Malignant Neoplasm in Familial Non-Medullary Thyroid Cancer Patients.
Capezzone M; Sagnella A; Cantara S; Fralassi N; Maino F; Forleo R; Brilli L; Pilli T; Cartocci A; Castagna MG
Front Endocrinol (Lausanne); 2022; 13():845954. PubMed ID: 35311228
[TBL] [Abstract][Full Text] [Related]
18. Post-translational Regulation of Radioactive Iodine Therapy Response in Papillary Thyroid Carcinoma.
Amit M; Na'ara S; Francis D; Matanis W; Zolotov S; Eisenhaber B; Eisenhaber F; Weiler Sagie M; Malkin L; Billan S; Charas T; Gil Z
J Natl Cancer Inst; 2017 Dec; 109(12):. PubMed ID: 30053080
[TBL] [Abstract][Full Text] [Related]
19. Redifferentiation of BRAF V600E-Mutated Radioiodine Refractory Metastatic Papillary Thyroid Cancer After Treatment With Dabrafenib and Trametinib.
Jafri S; Yaqub A
Cureus; 2021 Aug; 13(8):e17488. PubMed ID: 34595070
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of romidepsin for clinical activity and radioactive iodine reuptake in radioactive iodine-refractory thyroid carcinoma.
Sherman EJ; Su YB; Lyall A; Schöder H; Fury MG; Ghossein RA; Haque S; Lisa D; Shaha AR; Tuttle RM; Pfister DG
Thyroid; 2013 May; 23(5):593-9. PubMed ID: 23186033
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
